EFFECTIVENESS OF FRACTIONAL CARBONDIOXIDE LASER WITH TOPICAL METHOTREXATE VS TOPICAL PUVASOL IN TREATEMENT OF VITILIGO
Keywords:
laser treatment, Methotrexate, VitiligoAbstract
Background:
Vitiligo is an autoimmune disease characterized by patches of depigmentation on the skin. As skin is the major contributor to one’s social image and appearance, this disease impairs one’s quality of life to a significant extent. Dermatologists are continuously trying to find more and better treatment options, in addition to steroids, calcineurin inhibitors, immunomodulators and phototherapy. The aim of our study was to compare the effectiveness of topical methotrexate in combination with fractional carbon dioxide laser with topical psoralen with solar UVA (PUVASOL). Our hypothesis was that the Carbon dioxide laser-Topical Methotrexate combination is better than topical PUVASOL. It was a double blinded randomized Control Trial carried out in the Dermatology OPD of a tertiary care hospital in Rawalpindi over a period of 06 months i.e., 20.01.24 to 20.07.24.
Methods
36 patients meeting the inclusion criteria were included in the study after taking informed consent. Sampling was done by non-probability randomized sampling using lottery method. Half of them were treated with Fractional CO-2 laser followed by topical methotrexate12.5mg/ml application. Weekly sessions were done for 4 months. In the other group topical PUVASOL was used on alternate days for 04 months. 01 patient from each group was dropped. An independent observer noted the clinical improvement. Patient satisfaction and complications were also recorded.
Results
Statistically significant difference in results of Group A as compared to Group B, regarding clinical improvement and patient satisfaction were noted i.e., p= 0.039 and 0.002 respectively. There was no significant difference in the side-effect profile of both groups (p=0.59), with 44.1% patients having no side effect at all.
Conclusion: Fractional Carbon dioxide laser combined with topical methotrexate is better than topical PUVASOL in the treatment of vitiligo.
Keywords
Fractional carbon dioxide laser, Topical methotrexate, Topical PUVASOL, Vitiligo
References
1. Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology 2020;236(6):571–92.
2. Birol A, Kisa U, Kurtipek GS, Kara F, Kocak M, Erkek E, et al. Increased tumor necrosis factor alpha (TNF α) and interleukin 1 alpha (IL1 α) levels in the lesional skin of patients with nonsegmental vitiligo. Int J Dermatol 2006;45(8):992–3.
3. Belhadjali H, Amri M, Mecheri A, Doarika A, Khorchani H, Youssef M, et al. Vitiligo et qualité de vie: étude cas témoins. Ann Dermatol Venereol 2007;134(3 Pt 1):233–6.
4. Obioha O, Heath C, Grimes PE. Vitiligo and skin of color. In: Picardo M, Taïeb A, editors. Vitiligo. Cham: Springer 2019; p.233–44.
5. Cupertino F, Niemeyer Corbellini JP, Ramos E Silva M. Psychosomatic aspects of vitiligo. Clin Dermatol 2017;35(3):292–7.
6. Afify AA, Zuelfakkar NM, Eshafi MA. Fractional CO2 laser, platelet rich plasma and narrow band ultraviolet B in the treatment of vitiligo: a randomized clinical trial. Lasers Med Sci 2021;36(7):1479–86.
7. Zeid A, Ola M, Omar N, El Sharkawy D. The efficacy of combining fractional CO2 laser and tacrolimus ointment in the treatment of vitiligo. J Egypt Womens Dermatol Soc 2020;17(1):25–30.
8. HA S, MM S, HM E, Latif YA, OO AZ. Effect of carbon dioxide fractional laser on the levels of regulated upon activation normal T cell expressed and secreted serum chemokines and vitiligo clinical scoring in stable non segmental vitiligo: a case control study. Int J Curr Res Rev 2021;13(17):45–50.
9. Cunha PR, Scabine Pessotti N, Bonati Mattos C, Salai AF. New approach in the treatment of refractory vitiligo: CO2 laser combined with betamethasone and salicylic acid solution. Dermatol Ther 2017;30(1):e12410.
10. Basak PY, Adiloglu AK, Ceyhan AM, Tas T, Akkaya VB. The role of helper and regulatory T cells in the pathogenesis of vitiligo. J Am Acad Dermatol 2009;60(2):256–60.
11. Mansouri P, Rahbar M, Nilforoushzadeh MA, Shati M. Exploring the efficacy of fractional carbon dioxide laser as an add on combination to conventional therapies for treatment resistant vitiligo: a review article. J Lasers Med Sci 2023;14:e51.
12. Eleftheriadou V, Atkar R, Batchelor J, McDonald B, Novakovic L, Patel JV, et al; British Association of Dermatologists’ Clinical Standards Unit. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. Br J Dermatol 2022;186(1):18–29.
13. Goujon C, Bérard F, Dahel K, Guillot I, Hennino A, Nosbaum A, et al. Methotrexate for the treatment of adult atopic dermatitis. Eur J Dermatol 2006;16(2):155–8.
14. Abdelmaksoud A. Methotrexate for treatment of vitiligo. Dermatol Ther 2017;30(6):e12532.
15. Malik SS, Anwar A, Akhtar A. Effectiveness of methotrexate versus cyclosporine in the management of moderate to severe atopic dermatitis: meta analysis of randomised controlled trials. Pak Armed Forces Med J 2024;74(2):574–82.
16. Rudwaleit M, Yin Z, Siegert S, Grolms M, Radbruch A, Braun J, et al. Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4. Ann Rheum Dis 2000;59(4):311–4.
17. Majumdar S, Aggarwal BB. Methotrexate suppresses NF κB activation through inhibition of IκBα phosphorylation and degradation. J Immunol 2001;167(5):2911–20.
18. Abdelmaksoud A, Dave DD, Lotti T, Vestita M. Topical methotrexate 1% gel for treatment of vitiligo: a case report and review of the literature. Dermatol Ther 2019;32(5):e13013.
19. Balasaraswathy P, Kumar U, Srinivas CR, Nair S. UVA and UVB in sunlight: optimal utilization of UV rays in sunlight for phototherapy. Indian J Dermatol Venereol Leprol 2002;68(4):198–201.
20. Shenoi SD, Prabhu S; Indian Association of Dermatologists, Venereologists and Leprologists. Photochemotherapy (PUVA) in psoriasis and vitiligo. Indian J Dermatol Venereol Leprol 2014;80(6):497–504.
21. Abd-Elazim NE, Yassa HA, Mahran AM. Microdermabrasion and topical tacrolimus: a novel combination therapy of vitiligo. J Cosmet Dermatol 2020;19(6):1447–55.
22. Liu L, Wu Y, Zhang J, Gu H, Luan Q, Qian L, et al. Ablative fractional CO2 laser aided delivery of long acting glucocorticoid in the treatment of acral vitiligo: a multicenter, prospective, self bilateral controlled study. J Dermatolog Treat 2019;30(4):320–7.
23. Mohamed HA, Mohammed GF, Gomaa AH, Eyada MM. Carbon dioxide laser plus topical 5 fluorouracil: a new combination therapeutic modality for acral vitiligo. J Cosmet Laser Ther 2015;17(4):216–23.
24. Weshahy R, Abdelhamid MF, Sayed KS, El Desouky ED, Ramez SA. Efficacy and safety of combined fractional ablative CO2 laser and 5 fluorouracil in the treatment of acral vitiligo: an open, uncontrolled study. J Cosmet Dermatol 2022;21(11):5636–41.
25. Aickara D, Bashyam AM, Pichardo RO, Feldman SR. Topical methotrexate in dermatology: a review of the literature. J Dermatolog Treat 2022;33(1):512–7.
26. Kumar B, Sandhu K, Kaur I. Topical 0.25% methotrexate gel in a hydrogel base for palmoplantar psoriasis. J Dermatol 2004;31(10):798–801.
27. Das S, Sharadha M, Venkatesh MP, Sahoo S, Tripathy J, Gowda DV. Formulation and evaluation of topical nanoemulgel of methotrexate for rheumatoid arthritis. Int J Appl Pharm 2021;13(5):45–52.
28. Gharib KM, El Sharkawi YAF, Elmegrab NA, Ibrahim ASM. Assessment of role of topical methotrexate in the treatment of vitiligo: review article. Egypt J Hosp Med 2022;89(1):2334–40.
29. El Gayar MA, Atwa D, Girgis G, Marie L. Clinical, dermoscopic, and histopathologic evaluation of topical methotrexate 1% hydrogel versus topical calcipotriol 0.005% cream in the treatment of plaque psoriasis. J Cosmet Dermatol 2022;21(11):5779–89.
30. Ragab A, El Rewiny E, Zaky A. Evaluation of the efficacy of intralesional methotrexate versus intralesional triamcinolone acetonide in treatment of localized vitiligo: comparative intra individual study. Al Azhar Int Med J 2022;3(11):1788–94.
31. Rosmarin D, Pandya AG, Lebwohl M, Grimes P, Hamzavi I, Gottlieb AB, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet 2020;396(10244):110–20.
32. Kiran A, Khan S, Ahmed N, Ali M. Topical tacrolimus ointment alone versus in combination with microneedling for refractory stable vitiligo. J Coll Physicians Surg Pak 2024;34(5):514–7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Samina, Sakina Sadiq Malik, Ahmed Naveed Malik, Aayesha Rehman, Sajjad Ahmed, Ahsan Tameez-Ud-Din
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
